Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business
Biovail Corporation - Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis

Biovail Corporation - Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis - www.companiesandmarkets.com adds new report


Print article Print article
Refer this article Refer to a friend
© companiesandmarkets.com
2008-07-17 12:51:18 - Biovail Corporation - Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis - a new market research report on www.companiesandmarkets.com

www.companiesandmarkets.com/Summary-Company-Profile/Biovail-Corp ..

Introduction

Biovail is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products, utilizing advanced drug-delivery technologies. The company currently has over 20 distinct, proprietary drug-delivery technologies, and has access to other technologies through licensing agreements with development partners.



Scope

Contains corporate

strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies


Highlights

Biovail´s branded products in Canada include: Tiazac XC, Wellbutrin XL, Glumetza, Lescol, Lescol XL and Zyban. The company´s wholly-owned US subsidiary includes administrative, product distribution and related regulatory affairs functions. Its products include Cardizem CD, Ativan, Vaseretic, Vasotec, and Isordil.



Biovail derives its revenues primarily from the sales of pharmaceutical products developed and manufactured by the company, as well as sales of proprietary and in-license products;pharmaceutical clinical research and laboratory testing services, and product development activities in collaboration with third parties;



The company´s total revenues increased at a CAGR of 7.9% during 2002-2006, from $788 million to $1,067.7 million. This represents an absolute total growth of +$279.7 million for total revenues. The increase is primarily attributable to increased product sales.



Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization


www.companiesandmarkets.com/Summary-Company-Profile/Biovail-Corp ..


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: 01933674780

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.


Terms & Conditions | About us | Contact PR-inside.com